In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Modified form Tesamorelin | Synthetic analog GHRP-6 | |
|---|---|---|---|
| Identity | |||
| Kind | Modified form | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 288 | 942 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 43 (34 in people) | 32 (11 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 23 · 3 active1 more mentions it but does not test it | None registered | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Egrifta says: “Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Tesamorelin | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 22193 | 377117156104 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Inflammation markersMetabolic and weight | 5050 | 66 |
|---|
| Body weightMetabolic and weight | 39354 | 1616 |
|---|
| Adverse eventsWhole body | 29236 | 20614 |
|---|
| Glycemic controlMetabolic and weight | 28253 | 183132 |
|---|
| Body compositionMusculoskeletal | 2727 | 66 |
|---|
| PharmacokineticsPharmacology | 18792 | 221372 |
|---|
| LipidsMetabolic and weight | 22211 | 99 |
|---|
| Liver fat and liver functionLiver | 16142 | 11 |
|---|
| NeuroprotectionNervous system and cognition | 66 | 29254 |
|---|
| Immune responseImmune and inflammation | 55 | 2323 |
|---|
| SleepSleep | 11 | 963 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Tesamorelin is the same as Somatorelin, human GHRH(1-44) residues 1 to 44, with 2 added groups.
What is different
GHRP-6 differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 23 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Theratechnologies263 participantsAug 2007 to Oct 2008
Lipodystrophy · HIV Infections
Columbia University6 participants7 Feb 2018 to 30 Apr 2025
HIV Lipodystrophy Syndrome · Growth Hormone Deficiency · Body Composition
Theratechnologies412 participantsJun 2005 to Apr 2007
HIV Infections · Lipodystrophy
1 more mentions it but does not test it. They only measure it or name it in their text.
No registered trial that tests GHRP-6 found in ClinicalTrials.gov.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Tesamorelin | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: difference from placebo, in μg/liter | 92 μg/liter Treatment effect on IGF-I Dose studied: 2 mg12 monthsn = 602012 | No comparable result 15 randomized-trial results measure it in another way or another unit. |
| Body compositionMusculoskeletalCompared as: difference from placebo, in % | −15.4% Treatment effect on VAT Dose studied: 2 mg26 weeksn = 8062010 | No randomized trial result 6 results from other study designs. |
| LipidsCardiovascularCompared as: difference from placebo, in % | −12.3% Treatment effect on triglycerides Dose studied: 2 mg26 weeksn = 8062010 | No randomized trial result 9 results from other study designs. |
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in log2 fold change | −0.38 Log2 fold change CCL3 effect size 12 monthsn = 612021 | No randomized trial result 6 results from other study designs. |
| Heart functionCardiovascularCompared as: difference from placebo, in mm | −0.04 mm Treatment effect on cIMT Dose studied: 2 mg12 monthsn = 602012 | No randomized trial result 22 results from other study designs. |
| Body weightMetabolic and weightCompared as: difference from placebo, in cm2 | −42 cm2 Treatment effect Dose studied: 2 mg6 monthsn = 482014 | No randomized trial result |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in mg/dl | 7 mg/dL Treatment effect Dose studied: 2 mg6 monthsn = 482014 | No randomized trial result |
| Liver fat and liver functionLiverCompared as: difference from placebo, in % | −2.9% Net treatment effect Dose studied: 2 mg6 monthsn = 482014 |
92 μg/liter
Treatment effect on IGF-I
Dose studied: 2 mg12 monthsn = 602012
No comparable result
15 randomized-trial results measure it in another way or another unit.
16 results from other study designs.
18 results from other study designs.
No randomized trial result
1 result from other study designs.
−15.4%
Treatment effect on VAT
Dose studied: 2 mg26 weeksn = 8062010
No randomized trial result
6 results from other study designs.
−12.3%
Treatment effect on triglycerides
Dose studied: 2 mg26 weeksn = 8062010
No randomized trial result
9 results from other study designs.
−0.38 Log2 fold change
CCL3 effect size
12 monthsn = 612021
No randomized trial result
6 results from other study designs.
−0.04 mm
Treatment effect on cIMT
Dose studied: 2 mg12 monthsn = 602012
No randomized trial result
22 results from other study designs.
−42 cm2
Treatment effect
Dose studied: 2 mg6 monthsn = 482014
No randomized trial result
16 results from other study designs.
7 mg/dL
Treatment effect
Dose studied: 2 mg6 monthsn = 482014
No randomized trial result
18 results from other study designs.
−2.9%
Net treatment effect
Dose studied: 2 mg6 monthsn = 482014
No randomized trial result
1 result from other study designs.